PURPOSE: To evaluate the usefulness of 2-[(18)F]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography (FDG-PET/CT) in the early detection of resectable recurrences of colorectal cancer (CRC) and the impacts on the clinical disease management. METHODS: FDG-PET/CT was performed on patients with elevated serum carcinoembryonic antigen (CEA) levels >5 ng/mL (Group 1) or suspicious recurrences without rise in serum CEA levels (Group 2). The results were analyzed on the basis of histological data, disease progression, and/or clinical follow-up. Recurrence was defined as evidence of recurrent lesions within 6 months of the FDG-PET/CT scan. Resectable recurrences and changes in management were calculated based on medical records. RESULTS: In our study, 128 consecutive FDG-PET/CT analyses (n=49 in Group 1 and n=79 in Group 2) were performed on 96 recruited patients. Recurrences were proven in 63. The overall sensitivity, specificity, and accuracy of FDG-PET/CT were 98.4%, 89.2%, and 93.8%, respectively, and were 100%, 88.9%, and 95.9% in Group 1 and 96.9% and 89.4% and 92.4% in Group 2, respectively. Surgical resections were performed in 38.7% (12/31) of Group 1 patients and 53.1% (17/32) of Group 2 patients. FDG-PET/CT induced changes in planned management in 48.4% (62/128) of all patients, which included 63.3% (31/49) of Group 1 patients and 39.2% (31/79) of Group 2 patients (p=0.008). After a follow-up, 3.4% (1/29) of patients who underwent surgical resection of recurrent lesions and 34.3% (11/34) patients who did not undergo resection died at the end of study (p=0.004). CONCLUSIONS: The surgical resection of limited recurrent disease, as determined by FDG-PET/CT, improves the survival of CRC patients. FDG-PET/CT should be performed not only in patients with elevated serum CEA levels, but also in those in whom recurrences are suspected to improve the early detection of resectable disease.
PURPOSE: To evaluate the usefulness of 2-[(18)F]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography (FDG-PET/CT) in the early detection of resectable recurrences of colorectal cancer (CRC) and the impacts on the clinical disease management. METHODS: FDG-PET/CT was performed on patients with elevated serum carcinoembryonic antigen (CEA) levels >5 ng/mL (Group 1) or suspicious recurrences without rise in serum CEA levels (Group 2). The results were analyzed on the basis of histological data, disease progression, and/or clinical follow-up. Recurrence was defined as evidence of recurrent lesions within 6 months of the FDG-PET/CT scan. Resectable recurrences and changes in management were calculated based on medical records. RESULTS: In our study, 128 consecutive FDG-PET/CT analyses (n=49 in Group 1 and n=79 in Group 2) were performed on 96 recruited patients. Recurrences were proven in 63. The overall sensitivity, specificity, and accuracy of FDG-PET/CT were 98.4%, 89.2%, and 93.8%, respectively, and were 100%, 88.9%, and 95.9% in Group 1 and 96.9% and 89.4% and 92.4% in Group 2, respectively. Surgical resections were performed in 38.7% (12/31) of Group 1 patients and 53.1% (17/32) of Group 2 patients. FDG-PET/CT induced changes in planned management in 48.4% (62/128) of all patients, which included 63.3% (31/49) of Group 1 patients and 39.2% (31/79) of Group 2 patients (p=0.008). After a follow-up, 3.4% (1/29) of patients who underwent surgical resection of recurrent lesions and 34.3% (11/34) patients who did not undergo resection died at the end of study (p=0.004). CONCLUSIONS: The surgical resection of limited recurrent disease, as determined by FDG-PET/CT, improves the survival of CRC patients. FDG-PET/CT should be performed not only in patients with elevated serum CEA levels, but also in those in whom recurrences are suspected to improve the early detection of resectable disease.
Authors: Gershon Y Locker; Stanley Hamilton; Jules Harris; John M Jessup; Nancy Kemeny; John S Macdonald; Mark R Somerfield; Daniel F Hayes; Robert C Bast Journal: J Clin Oncol Date: 2006-10-23 Impact factor: 44.544
Authors: Jong-Ho Kim; Johannes Czernin; Martin S Allen-Auerbach; Benjamin S Halpern; Barbara J Fueger; Joel R Hecht; Osman Ratib; Michael E Phelps; Wolfgang A Weber Journal: J Nucl Med Date: 2005-04 Impact factor: 10.057
Authors: Jan D Soyka; Patrick Veit-Haibach; Klaus Strobel; Stefan Breitenstein; Alois Tschopp; Katja A Mende; Marisol Perez Lago; Thomas F Hany Journal: J Nucl Med Date: 2008-02-20 Impact factor: 10.057
Authors: Andrew M Scott; Dishan H Gunawardana; Ben Kelley; John G Stuckey; Amanda J Byrne; Jayne E Ramshaw; Michael J Fulham Journal: J Nucl Med Date: 2008-08-14 Impact factor: 10.057
Authors: Bruce E Hillner; Barry A Siegel; Dawei Liu; Anthony F Shields; Ilana F Gareen; Lucy Hanna; Sharon Hartson Stine; R Edward Coleman Journal: J Clin Oncol Date: 2008-03-24 Impact factor: 44.544
Authors: I Sobhani; E Tiret; R Lebtahi; T Aparicio; E Itti; F Montravers; C Vaylet; P Rougier; T André; J M Gornet; D Cherqui; C Delbaldo; Y Panis; J N Talbot; M Meignan; D Le Guludec Journal: Br J Cancer Date: 2008-02-26 Impact factor: 7.640
Authors: Patrick E Young; Craig M Womeldorph; Eric K Johnson; Justin A Maykel; Bjorn Brucher; Alex Stojadinovic; Itzhak Avital; Aviram Nissan; Scott R Steele Journal: J Cancer Date: 2014-03-15 Impact factor: 4.207
Authors: Brian D Nicholson; Bethany Shinkins; Indika Pathiraja; Nia W Roberts; Tim J James; Susan Mallett; Rafael Perera; John N Primrose; David Mant Journal: Cochrane Database Syst Rev Date: 2015-12-10